TVAX Biomedical to price initial public offering of its common stock

Roth Capital, Cantor Fitzgerald and Morgan Joseph TriAtrisan assist

By Devika Patel

Knoxville, Tenn., Nov. 7 - TVAX Biomedical, Inc. will price an initial public offering of its common stock, according to a Form S-1 filed Monday with the Securities and Exchange Commission. It expects its shares to trade on the Nasdaq exchange under the symbol "TVAX."

The deal also has a 30-day greenshoe option.

Roth Capital Partners, LLC is the bookrunning manager; Cantor Fitzgerald & Co. and Morgan Joseph TriArtisan LLC are the co-managers.

Proceeds will be used for general corporate purposes and to continue clinical testing of TVI-Brain-1.

The biotechnology company is based in Lenexa, Kan.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.